Caricamento...
Use of Raloxifene and Tamoxifen by Breast Cancer Risk Level in a Medicare-1 eligible Cohort
BACKGROUND: Raloxifene and tamoxifen are FDA approved for breast cancer risk reduction; in 2013, the US Preventive Services Task Force (USPSTF) recommended these drugs for breast cancer risk reduction in high-risk women. Information on use of raloxifene and tamoxifen for breast cancer risk reduction...
Salvato in:
| Pubblicato in: | Am J Obstet Gynecol |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
2018
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5970073/ https://ncbi.nlm.nih.gov/pubmed/29630889 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ajog.2018.03.031 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|